Macquarie Group LTD Akebia Therapeutics, Inc. Transaction History

Macquarie Group LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.27 - $2.24 $11,645 - $20,540	9,170 New	9,170 $16,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $1,078 - $2,257	-3,370 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$2.92 - $5.06 $3,016 - $5,226	-1,033 Reduced 23.46%	3,370 $11,000
Q2 2020 Aug 11, 2020	BUY	$6.67 - $13.58 $29,368 - $59,792	4,403 New	4,403 $60,000
Q3 2018 Nov 15, 2018	SELL	$7.44 - $10.65 $200,880 - $287,550	-27,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $211,365 - $261,954	23,100 Added 592.31%	27,000 $269,000
Q1 2018 May 11, 2018	SELL	$9.53 - $15.68 $145,809 - $239,904	-15,300 Reduced 79.69%	3,900 $37,000
Q4 2017 Feb 15, 2018	BUY	$14.24 - $19.59 $140,976 - $193,941	9,900 Added 106.45%	19,200 $286,000
Q3 2017 Nov 08, 2017	BUY	$13.06 - $19.67 $121,458 - $182,931	9,300	9,300 $183,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.